
1 anthracycline (a) v non-anthracycline (b) (OR)
Ackland 2001 6.25 (2.58, 15.13)
Subtotal (I-squared = .%, p = .) 6.25 (2.58, 15.13)
2 anthracycline (a) v mitoxantrone (b) (OR)
Alonso 1995 0.66 (0.11, 3.95)
Aviles 1994 0.26 (0.04, 1.60)
Bennett 1988 3.90 (0.78, 19.56)
Follezou 1987 2.97 (0.70, 12.64)
Gherlinzoni 1990 0.70 (0.22, 2.25)
Hausmaninger 1995 1.63 (0.40, 6.66)
Heidemann, 1993 0.46 (0.13, 1.57)
Henderson 1989 1.44 (0.57, 3.63)
Periti 1991 1.12 (0.33, 3.77)
Stewart 1997 1.06 (0.45, 2.51)
Subtotal (I-squared = 10.6%, p = 0.345) 1.09 (0.74, 1.61)
3 bolus (a) v continuous (b) (OR)
Casper 1991 2.13 (0.83, 5.46)
Hortobagyi 1989 3.47 (0.46, 26.39)
Shapira 1990 13.79 (4.05, 46.91)
Zalupski, 1991 1.20 (0.36, 4.01)
Subtotal (I-squared = 65.5%, p = 0.034) 3.04 (1.66, 5.58)
4 epirubicin (a) v doxorubicin (b) (OR)
Heidmann 1993 0.38 (0.07, 1.99)
Hernadi 1988b 0.13 (0.01, 2.12)
Homesley 1992 0.16 (0.06, 0.43)
Lahtinen 1991 0.38 (0.08, 1.83)
Perez 0.72 (0.21, 2.44)
Subtotal (I-squared = 1.7%, p = 0.397) 0.30 (0.16, 0.57)
5 liposomal doxorubicin (a) v doxorubicin (b) (RR)
Harris 2002 0.52 (0.27, 0.97)
O'Brien 2004 0.21 (0.11, 0.40)
Rifkin 2006 0.24 (0.03, 2.15)
Subtotal (I-squared = 48.5%, p = 0.143) 0.31 (0.20, 0.48)
6 liposomal doxorubicin (a) v epirubicin (b) (RR)
Chan, 2004 1.15 (0.47, 2.84)
Subtotal (I-squared = .%, p = .) 1.15 (0.47, 2.84)
7 cardioprotective agent (a) v none (b) (RR)
Lopez, 1998 0.29 (0.12, 0.74)
Marty, 2006 0.40 (0.20, 0.82)
Venturini, 1996 0.27 (0.09, 0.79)
Subtotal (I-squared = 0.0%, p = 0.785) 0.33 (0.20, 0.55)
.01 .1 .2 1 5 10 100
Favours a Favours b